GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytoMed Therapeutics Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$0.85−0.03 (-3.17%)
Close on Oct 19, 2026
Share price
−$1.4380 (−62.79%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
CytoMed Therapeutics Ltd grew revenue 366.7% to 324.39K SGD over fiscal 2025. Free cash flow was -4.34M SGD.
Revenue
324.39K SGD
+366.7% vs. a year earlier
Free cash flow
-4.34M SGD
FY2025
EPS, diluted
-0.34 SGD
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- 324.39K SGD
- Net income
- -3.98M SGD
- EPS, diluted
- -0.34 SGD
- Free cash flow
- -4.34M SGD
Valuation needs the share price. It fills in once daily prices are connected and converted from SGD.
Seven years at a glance
Fiscal years 2019 to 2025, SGD
Revenue
324.39K SGD+366.7% YoY
Net income
-3.98M SGD
EPS, diluted
-0.34 SGD
Free cash flow
-4.34M SGD
Reported period